Franklin Resources Inc. Acquires 395,744 Shares of Sanofi (NASDAQ:SNY)

Franklin Resources Inc. boosted its stake in Sanofi (NASDAQ:SNY - Free Report) by 13.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,407,452 shares of the company's stock after acquiring an additional 395,744 shares during the period. Franklin Resources Inc. owned 0.13% of Sanofi worth $208,106,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in SNY. Tidal Investments LLC boosted its stake in shares of Sanofi by 126.7% during the 3rd quarter. Tidal Investments LLC now owns 13,798 shares of the company's stock worth $795,000 after acquiring an additional 7,711 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Sanofi in the 3rd quarter valued at approximately $219,000. World Investment Advisors LLC lifted its stake in Sanofi by 1,020.5% in the 3rd quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock valued at $2,791,000 after buying an additional 44,108 shares in the last quarter. Sanctuary Advisors LLC lifted its stake in Sanofi by 8.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 96,135 shares of the company's stock valued at $5,540,000 after buying an additional 7,556 shares in the last quarter. Finally, Rehmann Capital Advisory Group lifted its stake in Sanofi by 9.1% in the 3rd quarter. Rehmann Capital Advisory Group now owns 14,599 shares of the company's stock valued at $844,000 after buying an additional 1,213 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Citigroup upgraded Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi has a consensus rating of "Moderate Buy" and an average target price of $57.50.

Sanofi Stock Down 0.4 %

NASDAQ:SNY traded down $0.19 on Friday, reaching $46.80. The stock had a trading volume of 3,464,494 shares, compared to its average volume of 2,282,094. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average of $51.02 and a 200 day moving average of $52.07. The stock has a market cap of $118.77 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. During the same quarter last year, the company posted $2.55 earnings per share. The company's quarterly revenue was up 12.3% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 4.06 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.